Instil Bio, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.0M | $4.3M | $0 | $0 | $138.0K |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | — | — | $39.6M | $107.3M | $19.4M |
| SG&A Expense | $27.2M | $44.2M | $47.6M | $48.3M | $14.4M |
| Operating Income | $-78.6M | $-73.5M | $-159.2M | $-155.6M | $-33.6M |
| Operating Margin | -876.2% | -1,723.5% | — | — | -24,379.7% |
| Interest Expense | — | — | $5.2M | $0 | — |
| Pretax Income | $-71.4M | $-74.1M | $-156.1M | $-156.8M | $-37.6M |
| Income Tax Expense | $0 | — | $0 | $39.0K | $151.0K |
| Net Income | $-71.4M | $-74.1M | $-156.1M | $-156.8M | $-37.7M |
| Net Margin | -795.9% | -1,737.4% | — | — | -27,346.4% |
| EPS (Basic) | $-10.70 | $-11.39 | $-24.00 | $-1.48 | $-0.34 |
| EPS (Diluted) | $-10.70 | $-11.39 | $-24.00 | $-1.48 | $-0.34 |
| Shares Outstanding (Basic) | 6.7M | 6.5M | 6.5M | 106.0M | 112.0M |
| Shares Outstanding (Diluted) | 6.7M | 6.5M | 6.5M | 106.0M | 112.0M |
| Dividends Per Share | — | — | — | — | — |